# A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)

> **NCT00251589** · PHASE1,PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 23 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** Vorinostat
- **DRUG:** Vorinostat
- **DRUG:** Vorinostat
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT00251589
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** This trial is being closed based on lack of substantive efficacy, slow accrual and overall tolerance in patients treated to date.
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251589, "A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00251589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*